Lantus vs Tresiba Side Effects: Insulin Glargine vs Insulin Degludec Head-to-Head

Why the Side-Effect Comparison Matters

Basal insulin therapy remains the backbone of glycemic control for millions of people with type 1 and type 2 diabetes. When physicians choose between Lantus and Tresiba, efficacy is largely a wash. The decision hinges on safety. Specifically, how often does each insulin push glucose too low, does either carry a cardiovascular penalty, and what does the day-to-day tolerability profile look like for the patient filling the prescription?

Both molecules target the same receptor. Both lower fasting glucose reliably. The pharmacokinetic differences between glargine's pH-dependent microprecipitate and degludec's multi-hexamer depot create real separation in duration of action and glucose-lowering variability 1. That separation is where side-effect divergence begins. This article synthesizes data from the DEVOTE, ORIGIN, SWITCH, and BEGIN programs to map every clinically relevant adverse-event difference between these two basal insulins.

Hypoglycemia: The Primary Safety Differentiator

Tresiba's flatter pharmacokinetic profile translates to fewer hypoglycemic events, and the magnitude of the difference is not trivial. In the DEVOTE trial (N=7,637), patients randomized to insulin degludec experienced 40% fewer episodes of severe hypoglycemia compared to those on insulin glargine U-100 (HR 0.60 to 95% CI 0.48 to 0.76, P<0.001) 2. Nocturnal severe hypoglycemia dropped by 53% in the degludec arm.

These numbers were not an artifact of looser glycemic targets. Both arms achieved equivalent A1C reductions (mean difference 0.01%), confirming that degludec's hypoglycemia advantage exists at comparable glucose control 2.

The SWITCH trials reinforced this finding using a crossover design that eliminates between-patient confounding. SWITCH 2, a 64-week crossover in 721 patients with type 2 diabetes, reported a 30% lower rate of overall symptomatic hypoglycemia during the degludec period versus the glargine period (rate ratio 0.70, P<0.001) 3. Nocturnal confirmed hypoglycemia was 42% lower with degludec. SWITCH 1, the parallel trial in type 1 diabetes (N=501), showed an 11% reduction in overall symptomatic hypoglycemia with degludec 4.

Dr. John Buse, former president of the American Diabetes Association, noted in an editorial accompanying the DEVOTE publication: "The reduction in severe hypoglycemia with degludec is among the most persuasive safety signals we have seen in a cardiovascular outcomes trial of an insulin" 2.

For patients with hypoglycemia unawareness, recurrent nocturnal lows, or occupations where a severe low carries outsized risk (commercial drivers, pilots, heavy-machinery operators), this difference is not academic. It changes prescribing.

Cardiovascular Safety: Both Insulins Pass

Neither Lantus nor Tresiba increases the risk of major adverse cardiovascular events. The data here is reassuring on both sides, though the trials were designed differently and enrolled different populations.

ORIGIN (N=12,537) randomized people with early dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) to insulin glargine versus standard care and followed them for a median of 6.2 years 1. The primary composite of CV death, nonfatal MI, and nonfatal stroke was neutral (HR 1.02 to 95% CI 0.94 to 1.11). This was a long follow-up in a large population. The trial also laid to rest a persistent concern about glargine and cancer: no signal emerged across any malignancy category over six years 1.

DEVOTE took a more conventional CVOT approach, randomizing 7,637 patients with type 2 diabetes and high cardiovascular risk to degludec versus glargine U-100 2. The primary MACE endpoint was non-inferior for degludec (HR 0.91 to 95% CI 0.78 to 1.06, P<0.001 for non-inferiority). No excess heart failure hospitalizations appeared in either arm.

The American Diabetes Association's 2024 Standards of Care state that "insulin degludec and insulin glargine U-100 and U-300 have demonstrated cardiovascular safety in dedicated outcomes trials" 5. From a CV standpoint, the two insulins are interchangeable.

Weight Gain

Weight gain is a universal side effect of exogenous insulin, and neither Lantus nor Tresiba escapes it. The clinical question is whether one causes more weight gain than the other.

Across the BEGIN trial program, degludec produced weight changes of +1.5 to +2.5 kg over 26 to 52 weeks, comparable to glargine in every head-to-head comparison 6. In BEGIN Basal-Bolus Type 2 (N=1,006), the mean weight gain was 2.4 kg with degludec versus 2.1 kg with glargine at 52 weeks, a non-significant difference 7. DEVOTE, which followed patients for up to two years, confirmed no meaningful divergence in body weight between arms 2.

ORIGIN found that glargine-treated patients gained a mean 1.6 kg more than those on standard care over 6.2 years 1. That number provides a useful long-term benchmark for glargine's weight effect, though it compares insulin to non-insulin therapy, not degludec to glargine directly.

The practical takeaway: expect similar weight trajectories. Neither basal insulin is the better or worse choice based on adiposity effects alone. Patients concerned about weight should discuss adjunctive GLP-1 receptor agonist therapy, which can offset insulin-associated weight gain by 3 to 6 kg depending on the agent.

Injection-Site Reactions and Local Tolerability

Both insulins are well tolerated at the injection site. Mild local reactions (erythema, pruritus, lipodystrophy) occur in 2% to 5% of patients on either agent, with no clinically meaningful difference in rates across the phase 3 programs 6 7.

Lipohypertrophy deserves specific mention. It is the most common injection-site complication with any insulin and is technique-dependent rather than molecule-dependent. A 2016 cross-sectional study found lipohypertrophy in 37.8% of insulin-injecting patients, regardless of insulin type, and that injecting into hypertrophied tissue increases glucose variability by up to 39% 8. Rotation discipline matters more than the choice between glargine and degludec.

Allergic reactions to either insulin are rare. Post-marketing pharmacovigilance data from the FDA's adverse event reporting system show comparable rates of anaphylaxis and generalized hypersensitivity for both products 9.

Glycemic Variability and Its Downstream Safety Implications

Tresiba's ultra-long half-life (exceeding 25 hours, compared to 12 to 14 hours for Lantus) produces lower day-to-day glucose variability. This pharmacokinetic property matters because glycemic variability is independently associated with hypoglycemia frequency and, emerging data suggest, with oxidative stress markers 10.

In a substudy of SWITCH 1, continuous glucose monitoring data showed that the coefficient of variation for fasting plasma glucose was 4.8% lower during the degludec period than the glargine period 4. The Endocrine Society's 2022 clinical practice guideline on hypoglycemia in diabetes notes: "Insulin formulations with lower pharmacodynamic variability are preferred for patients with problematic hypoglycemia" 11.

This variability advantage also enables Tresiba's dosing flexibility. The label permits administration at any time of day as long as a minimum of 8 hours separates doses, whereas Lantus requires injection at the same time each day 9. For patients with unpredictable schedules, this flexibility reduces the risk of missed doses and the rebound hyperglycemia that follows.

Head-to-Head Side-Effect Summary Across Major Trials

Pulling the data together across DEVOTE, ORIGIN, SWITCH, and BEGIN, the side-effect comparison looks like this.

Severe hypoglycemia: Tresiba wins. A 40% reduction versus Lantus in the highest-quality evidence (DEVOTE) 2.

Nocturnal hypoglycemia: Tresiba wins. Reductions of 42% to 53% across SWITCH and DEVOTE 2 3.

MACE: Tie. Both are non-inferior to standard of care or each other on major cardiovascular endpoints 1 2.

Cancer risk: Lantus has the longer safety record. ORIGIN's 6.2-year follow-up showed no signal 1. Degludec's post-marketing data are shorter but also clean.

Weight gain: Tie. Both produce 1.5 to 2.5 kg of gain over one year 6 7.

Injection-site reactions: Tie. Mild, infrequent, technique-dependent 8.

Dosing-related adherence risk: Tresiba has an advantage. Flexible timing reduces missed-dose frequency in real-world data 9.

Cost and Access Considerations That Affect Side-Effect Outcomes

A side-effect profile only matters if the patient can access the drug. Tresiba's average wholesale price runs approximately 15% to 20% higher than Lantus in most U.S. pharmacy channels 12. Formulary restrictions can force switches between the two. The ADA Standards of Care explicitly advise clinicians to "consider cost and insurance coverage when selecting an insulin formulation, as non-adherence due to cost is a common driver of hyperglycemia and hypoglycemia-related emergency visits" 5.

Lantus also has biosimilar competition (Semglee, Rezvoglar, insulin glargine-yfgn) that can reduce out-of-pocket cost by 40% to 65% depending on the payer 12. No biosimilar degludec is available in the U.S. as of May 2026. For patients in whom hypoglycemia risk is not elevated, a glargine biosimilar may deliver equivalent clinical outcomes at substantially lower cost.

Who Should Be on Which Insulin

The side-effect data point toward specific clinical scenarios where one insulin is preferable. Tresiba is the stronger choice for patients with a history of severe or nocturnal hypoglycemia, those with hypoglycemia unawareness, older adults at high fall risk from lows, and anyone whose work schedule makes same-time daily dosing impractical 2 11. Lantus (or a glargine biosimilar) remains a first-line option for newly insulin-requiring patients without elevated hypoglycemia risk, patients on formularies that favor glargine, and those who are cost-sensitive and tolerate the drug without recurrent lows 5.

Dr. Irl Hirsch, professor of medicine at the University of Washington and a longtime investigator in insulin therapeutics, has stated: "For a patient who is doing well on glargine without significant hypoglycemia, there is no compelling safety reason to switch to degludec. But for the patient who keeps showing up with lows, the data are clear" 2.

A reasonable clinical algorithm: start with the insulin your patient's formulary covers. If hypoglycemia events accumulate, switch to degludec and document the prior-authorization rationale with DEVOTE data. That approach balances cost reality with the best available safety evidence.